Core Insights - BiomX Inc. is presenting positive topline results from its Phase 2 trial evaluating BX211 for the treatment of Diabetic Foot Osteomyelitis (DFO) at the Biomed Israel 2025 conference [1][2] - BX211 is a phage therapy targeting DFO associated with Staphylococcus aureus, a significant cause of amputation in diabetic patients [3][4] Presentation Details - The oral presentation titled "Precision Phage Therapy for Chronic Diabetic Foot Infections" will take place on May 21, 2025, from 12:15 to 2:15 pm IST at the InterContinental David Tel Aviv [2] - The session focuses on immunology and inflammation, highlighting opportunities in biopharma [2] BX211 Trial Results - The Phase 2 trial demonstrated that BX211 was safe and well-tolerated, with a statistically significant reduction in ulcer size (p = 0.046 at week 12; p = 0.052 at week 13) [3] - A separation from placebo was observed starting at week 7, with a difference greater than 40% by week 10 [3] - Statistically significant improvements were also noted in ulcer depth (p=0.048) and reduction of ulcer area expansion (p=0.017) [3] - The treatment period lasted 12 weeks, during which all patients received standard care, including systemic antibiotic therapy [3] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies for chronic diseases with unmet medical needs [4] - The company utilizes its BOLT platform to customize phage compositions targeting specific bacterial pathogens [4]

Group 1 - The conference call is focused on BiomX's first quarter 2025 financial results and updates on business and programs [3] - The quarterly report on Form 10-Q will be filed with the Securities and Exchange Commission, and a press release was made available at 6:30 a.m. Eastern time [3] - A replay of the conference call will be accessible in the Investors section of the company's website [3] Group 2 - The call includes forward-looking statements regarding the company's cash sufficiency, pipeline, clinical trial designs, expected discussions with regulatory agencies, and potential benefits of product candidates [4] - The company emphasizes that past and current clinical trials do not guarantee future results [5]

BiomX (PHGE) Q1 2025 Earnings Call May 15, 2025 02:00 PM ET Company Participants Marina Wolfson - CFO & SecretaryJonathan Solomon - CEO & Board Member Conference Call Participants Joseph Pantginis - MD & Senior Healthcare AnalystYale Jen - Senior Managing Director & Senior Biotech Analyst Operator Greetings, and welcome to the BioMix First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the form ...

BiomX (PHGE) Q1 2025 Earnings Call May 15, 2025 02:00 PM ET Speaker0 Greetings, and welcome to the BioMix First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to Marina Wolfson, Chief Financial Officer. Thank you. You may begin. Speaker1 Thank you, and welcome to the Bionics conference ca ...

In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial The Company will host a conference call and webcast today at 2:00 PM ...

BiomX (PHGE) Q4 2024 Earnings Call April 01, 2025 12:22 PM ET Company Participants Marina Wolfson - CFO & SecretaryJonathan Eitan Solomon - CEO and Board MemberJoe Pantginis - Managing Director Conference Call Participants Yale Jen - Senior Managing Director & Senior Biotech Analyst Operator Greetings, and welcome to today's BioMx Investor Presentation. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference ...

Core Viewpoint - BiomX Inc. announced positive topline safety and efficacy results from its Phase 2 trial of BX211, a phage therapy for diabetic foot osteomyelitis (DFO) associated with Staphylococcus aureus, indicating significant potential in addressing unmet medical needs in this area [1][2][3]. Summary of Phase 2 BX211 Results - The Phase 2 trial was a randomized, double-blind, placebo-controlled study involving 41 patients, with a treatment ratio of 2:1, where 26 received BX211 and 15 received placebo [4]. - BX211 was found to be safe and well-tolerated, showing a statistically significant reduction in ulcer size (Percent Area Reduction, PAR) with p-values of 0.046 at week 12 and 0.052 at week 13, with a notable separation from placebo starting at week 7 and a difference greater than 40% by week 10 [3][12]. - Statistically significant improvements were also observed in ulcer depth at week 13 (p=0.048) and in reducing the expansion of ulcer area (p=0.017) compared to placebo [12]. - The study demonstrated favorable trends across additional clinical parameters, including evidence of resolving DFO by MRI/X-ray and improvement in the Wagner scale [12]. Future Plans - Following the successful Phase 2 results, BiomX plans to initiate a Phase 2/3 trial of BX211, pending feedback from the U.S. Food and Drug Administration (FDA) [1][9]. - The company will present additional data from the Phase 2 study at upcoming scientific conferences [5]. Industry Context - The results highlight the therapeutic potential of phage therapy, particularly in treating infections where antibiotic resistance is a concern, addressing a significant unmet need in DFO, which currently leads to a high rate of lower extremity amputations [2][12]. - The company emphasizes the broader relevance of phage therapy in modern conflict scenarios and rising antibiotic-resistant infections, indicating a shift in treatment paradigms for chronic infections [2].